Company Overview and News

Ethical fashion ranking: How New Zealand's largest retailers and brands fare

An advocate for ethical fashion retail says top brands are not doing enough to protect workers in their international supply chains despite attempts being made.

The rise of the cowboy toy importer: Do New Zealand's regulatory standards need a revamp?

Unsafe toys are being sold through discount stores, weekend market stalls and cowboy online sellers, putting young children at risk, says the head of New Zealand's largest toy distributor.

Jobs saved as plans to close Kaikohe Warehouse shelved

The Warehouse has backtracked on plans to close its Kaikohe store in Northland at the end of June, saving 33 permanent jobs.

Jobs saved as plans to close Kaikohe Warehouse shelved

The Warehouse has backtracked on plans to close its Kaikohe store in Northland at the end of June, saving 33 permanent jobs.

Dozens of jobs to go as Kaikohe Warehouse closes

The Warehouse says it's closing its Kaikohe store in Northland at the end of June, with 33 permanent jobs to go.

Shane Jones lashes out at 'anti-Kiwi companies' shunning Northland

"Anti-Kiwi" NZX companies are shunning Northland, according to Regional Development Minister Shane Jones, who says he's "had a gutsful" of businesses pulling out of places like Kaikohe.

The Warehouse to shut in Kaikohe by June: Shane Jones 'genuinely surprised'

National retailer The Warehouse told staff yesterday it was shutting its Kaikohe store because it has been unable to negotiate an extension of its lease on the premises and a union says 60 jobs will be lost.

Controversial data firm Cambridge Analytica linked with The Warehouse

The Warehouse Group has confirmed it has links with the data firm at the centre of an international scandal involving the misuse of Facebook users' personal information.

NZ shares rise; A2 gains, Restaurant Brands, Tegel fall on earnings

New Zealand shares rose, led by A2 Milk Co, while Restaurant Brands and Tegel dropped after updating their earnings guidance.

Warehouse Group half-year profits up

The country's largest retailer, the Warehouse Group, has made a better half-year profit as it cut its losses from its financial services business.

The Warehouse Group first-half profit falls as business overhaul continues

The Warehouse Group’s [NZX:WHS] interim earnings and profit are down, as it continues to overhaul the business.

Warehouse profit drops 16 pct after roll out new sales strategy

The Warehouse Group today announced an adjusted net profit after tax result of $37.7 million for first six months of the 2018 financial year - down 16 percent on the $45 million posted in 2017.

Warehouse exec took Russian businessman with links to Putin to Trump's inauguration

A executive now working for The Warehouse took along a wealthy Russian entrepreneur with links to Vladimir Putin to Donald Trump's inauguration

NZ shares drop 1.4 per cent on foreign selling

New Zealand shares fell over 1 per cent as foreign investors sold back their stakes, with A2 Milk Co and Meridian Energy hit hardest.

The Warehouse Group forecasts first-half earnings to fall by up to 28%

The Warehouse Group's reinvented senior management incentive programme will eat into the NZX-listed retailer's first-half earnings.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...